AssetMark’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
AssetMark's CORT Position: Q3 2026 in Review
AssetMark increased its Corcept Therapeutics (CORT) stake by 3.5% in Q3 2026, buying an estimated $133K and bringing the position to 36,521 shares worth $4.21M. The position accounts for 0.01% of the portfolio, ranked #775.
AssetMark first reported a position in CORT in Q2 2020 and has held it in 26 quarters since. The position peaked at $8.11M in Q1 2025. 403 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- AssetMark held 36,521 shares of Corcept Therapeutics worth $4.21M as of Q3 2026.
- AssetMark bought 1,233 Corcept Therapeutics shares in Q3 2026, an estimated $133K.
- Corcept Therapeutics made up 0.01% of AssetMark's portfolio in Q3 2026, its #775 holding.
- AssetMark first reported a position in Corcept Therapeutics in Q2 2020 and has held it in 26 quarters since.
- AssetMark's Corcept Therapeutics position peaked at $8.11M in Q1 2025.
- 403 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.